Orion Portfolio Solutions LLC Sells 12,934 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Orion Portfolio Solutions LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 82.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,771 shares of the biopharmaceutical company’s stock after selling 12,934 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Regeneron Pharmaceuticals were worth $2,501,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $31,000. MCF Advisors LLC increased its stake in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $37,000. Finally, Bruce G. Allen Investments LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $40,000. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The disclosure for this sale can be found here. Insiders sold 55,243 shares of company stock worth $53,955,443 over the last three months. Insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Bank of America upped their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. BMO Capital Markets upped their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Finally, Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $989.36.

Check Out Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

REGN opened at $966.49 on Thursday. The firm’s fifty day simple moving average is $945.50 and its two-hundred day simple moving average is $918.38. The company has a market cap of $106.50 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.00 and a beta of 0.17. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.34 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.